<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062034</url>
  </required_header>
  <id_info>
    <org_study_id>RDNP-20100102</org_study_id>
    <nct_id>NCT02062034</nct_id>
  </id_info>
  <brief_title>Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy</brief_title>
  <official_title>Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ubiquinone and combined antioxidant
      therapy on progression, clinical regression, oxidative stress markers and mitochondrial
      dysfunction in non-proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are interested in demonstrating the efficacy of Ubiquinone and combined
      antioxidant therapy in the pharmacological management of diabetic retinopathy since early
      stages.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative Stress markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>In this study the oxidative stress markers are composed of lipid peroxidation, nitric oxide, erythrocyte glutathion peroxidase activity, erythrocyte catalase activity, total antioxidant capacity and erythrocyte membrane fluidity.
Lipid peroxidation (baseline and final values) given as malondialdehyde (MDA) and 4-hydroxyalkenals (4HDA) expressed in μmol/L
Nitric oxide (NO) Levels of the NO catabolites nitrites/nitrates expressed in pmol/mL (baseline and final values)
Erythrocyte glutathion peroxidase activity measured in U/min/mg protein (baseline and final values)
Erythrocyte catalase activity expressed in U/mg protein (baseline and final values)
Total antioxidant capacity measured in milliequivalent/mL (baseline and final values)
Erythrocyte membrane fluidity, calculated using the fluorescence ratio of the excimer (Ie) to monomer (Im). The Ie/Im ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial dysfunction markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>In this study the mitochondrial dysfunction markers are composed of hydrolysis of adenosine triphosphate and membrane fluidity in submitochondrial particles of platelets.
Hydrolysis of adenosine triphosphate: The hydrolytic activity of mitochondrial F0/F1-ATPase (F0/F1-adenosine triphosphatase) was measured as the liberation of inorganic phosphate from platelet mitochondria. Expressed in nmol of phosphate. Baseline and final values.
Membrane fluidity in submitochondrial particles of platelets. Calculated usig the fluorescence ratio of the excimer (Ie) to monomer (Im). The Ie/Im ratio. (Baseline and final values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression and regression of non-proliferative diabetic retinopathy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluated with International clinical diabetic retinopathy disease severity scale, fluorescein angiography and color fundus photographs.
Baseline and final stage.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Security profile</measure>
    <time_frame>24 weeks</time_frame>
    <description>In this study the security profile markers are composed of intraocular pressure, visual acuity, renal function, and liver profile.
Intraocular pressure. expressed in mmHg (baseline and final values) Visual acuity measured in decimal scale (baseline and final values) Renal function: serum urea (mg/dL), serum creatinine (mg/dL). (Baseline and final values) Liver profile: total serum bilirubin (mg/dL), indirect bilirubin (mg/dL), direct bilirubin (mg/dL) (Baseline and final values).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Ubiquinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg daily of oral ubiquinone for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined antioxidant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. 100mg daily oral intake for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubiquinone</intervention_name>
    <description>400mg daily of oral ubiquinone for 24 weeks</description>
    <arm_group_label>Ubiquinone</arm_group_label>
    <other_name>coenzyme Q10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined antioxidant therapy</intervention_name>
    <description>(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks</description>
    <arm_group_label>Combined antioxidant therapy</arm_group_label>
    <other_name>lutein</other_name>
    <other_name>zeaxanthin</other_name>
    <other_name>astaxanthin</other_name>
    <other_name>vitamin C</other_name>
    <other_name>vitamin E</other_name>
    <other_name>zinc</other_name>
    <other_name>copper</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus

          -  Patients with non proliferative diabetic retinopathy

          -  Glycated hemoglobin &lt; 12.0%

          -  Signing of informed consent

        Exclusion Criteria:

          -  Patients with clinically significant macular edema

          -  Patients with diabetic retinopathy advanced lesions that have required or require
             specific treatment (laser, vitrectomy)

          -  Pretreatment with argon laser or excimer laser Ophthalmology surgery

          -  Any other associated ocular pathology (glaucoma, cataracts, changing cornea dystrophy,
             macular degeneration)

          -  Pregnancy, lactation, inadequate use of contraception

          -  Antioxidant drug and/or supplements six months previous to enrollment

          -  Renal and/or hepatic failure

          -  Age under 30 or over 75 years

          -  Severe cardiovascular disease (myocardial infarction, stroke, severe peripheral
             vasculopathy)

          -  Blood dyscrasias

          -  Have or have had cancer or other serious illness

          -  Neurodegenerative process

          -  Allergy to vitamins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandra G. Miranda-Díaz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A. Castellanos-González, M.Sc.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adolfo D. Rodriguez-Carrizalez, M.Sc.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Research Unit, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/record/NCT01622777</url>
    <description>The effect of rosuvastatin in Diabetic Polyneuropathy: A Phase 2a Randomized Double-blind Placebo-controlled Study</description>
  </link>
  <results_reference>
    <citation>Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, Troyo-Sanromán R, Ortiz-Lazareno PC, Cárdenas-Meza MA, Pascoe-González S, Miranda-Díaz AG. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications. 2012 Jul-Aug;26(4):352-8. doi: 10.1016/j.jdiacomp.2012.04.004. Epub 2012 May 16.</citation>
    <PMID>22595020</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Alejandra Guillermina Miranda Diaz</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Oxidative stress</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <keyword>Ubiquinone</keyword>
  <keyword>Antioxidant combined therapy</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Copper</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 25, 2014</submitted>
    <returned>May 27, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

